Blood analysis is one of the most frequently performed clinical routines in modern medical care. Hemolysis is one of the most common errors affecting blood test results, and it leads to delayed treatment for the patients and increased costs for the healthcare system. Swedish medtech company Hemcheck has developed a concept to detect hemolysis in blood samples through a range of products and services offered to healthcare providers, thus contributing to better care flow, reduced costs and, above all, increased patient safety. CEO Joen Averstad visited the BioStock Studio to tell us more about the company and its upcoming milestones.
Watch the interview with Hemcheck‘s CEO Joen Averstad below: